This page shows the latest Moderna news and features for those working in and with pharma, biotech and healthcare.
Elle Taylor from Ammanford, a 24-year-old unpaid carer, was the first to receive the Moderna vaccine today. ... The results from this trial showed that the Moderna vaccine has 94% efficacy against the virus and 100% efficacy against severe disease.
Unlike an RNA vaccine used by Moderna and Pfizer’s, the AZ/Oxford vaccine is made from a weakened version of a common cold virus from chimpanzees.
mRNA-based vaccines, such as Pfizer/BioNTech and Moderna’s respective jabs, have higher efficacy rates compared to both CanSinoBIO and J&J’s vaccines, but also require ultra-low storage
The CHMP has also recommended approving the addition of a new manufacturing site for the production of the active substance, as well as finished product intermediates, for Moderna’s COVID-19 ... vaccine. The new manufacturing lines, located at a
The phase 2 trial amendment has enrolled 60 participants who have already received Moderna’s original mRNA-1273 vaccine. ... Vaccination with Moderna’s original COVID-19 vaccine produced neutralising antibodies against both the UK and SA variants,
Another vaccine maker – Moderna – is also developing a variant-specific vaccine candidate, mRNA-1273.351, against the B.1.351 variant discovered in South Africa. ... The company is also developing a multivalent booster candidate, mRNA-1273.211, that
More from news
Approximately 43 fully matching, plus 104 partially matching documents found.
So far the Pfizer/BioNTech, Moderna and AstraZeneca/Oxford University vaccines have all received approval in the UK and other countries for the very disease that put all these changes into
Moderna was the first group to test a vaccine in humans, using its mRNA platform to enter the clinic in record time. ... Moderna thinks its vaccine could be available to healthcare professionals as early as the autumn, but the accepted timeline for
At the front of the race is Cambridge, Massachusetts-based biotech company Moderna, which dosed the first patient in the US in March with its COVID-19 vaccine candidate. ... To win approval for public use, a larger phase 2 trial is need, which Moderna
Abbott, Allergan, Celgene, Moderna, Pfizer and Takeda feature in this month's pharma deals round-up. ... up. Turning to the battle against the Zika virus, BARDA announced three more grants for vaccine development to Takeda (up to $312m), Moderna [up to
Apart from the $200m upfront cash payment to Moderna, there were no other financials disclosed. ... licence. 230. Moderna Therapeutics/ Merck &Co. mRNA-based personalised cancer vaccines; exclusive for Keytruda combinations (discovery).
More from intelligence
Approximately 1 fully matching, plus 9 partially matching documents found.
Horning has also recently joined the board of directors at Moderna, a clinical-stage biotechnology company based in Cambridge, Massachusetts.
Prior to this, he was chief scientific officer at Moderna Therapeutics and has held the same role at Tolerx.
Dr Slaoui takes on the role alongside his other board positions, which include chairman of the board at Galvani Bioelectronics, and on the boards of Artisan Biosciences, Moderna Therapeutics and Sutovax.
US-based biotech Moderna Therapeutics has appointed Israel Ruiz to its board of directors to serve as audit committee chair. ... Dr Noubar Afeyan, co-founder and chairman of Moderna Therapeutics, said: “We are delighted to welcome Israel to Moderna's
Bringing over 30 years of clinical development experience to the role, he joins from Moderna Therapeutics where he most recently served as president and chief scientific officer.
More from appointments
Approximately 3 fully matching, plus 6 partially matching documents found.
The following month, it happened again. Cambridge, Massachusetts-based Moderna said it had slowed enrolment in its phase 3 COVID-19 vaccine trial to ensure they were getting a representative population. ... Moderna effectively sacrificed potential sales,
15]. In fact, Moderna slowed down recruitment for its COVID-19 vaccine trial specifically to address a shortfall in recruitment from ethnically diverse populations for an illness that has been shown
Since then, other good news has followed, with collaborations, including Moderna and AstraZeneca, publishing similarly positive results. ... Since this initial announcement, other good news in vaccine development has followed, with companies and
Since then, other good news has followed, with collaborations, including Moderna and AstraZeneca, publishing similarly positive results.
More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.
Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...